• Assembly Biosciences dosed the first two participants in a Phase 2 trial of oral ABI-6250 for chronic hepatitis delta virus infection.
• The trial targets approximately 80 participants, testing two once-daily doses for safety and antiviral activity.
• Initial Phase 2 data are expected in the fourth quarter of 2027.
• Phase 1a results supported further development, with a mean half-life of approximately four days supporting once-daily dosing.
• Gilead holds an exclusive licensing option for ABI-6250 for $90 million through Phase 2 completion and review of the option data package.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291600PRIMZONEFULLFEED9856448) on October 29, 2026, and is solely responsible for the information contained therein.